Omalizumab Efficacy, Drug Survival and Clinical and Serological Biomarkers in Chronic Inducible Urticaria
Chronic inducible urticaria is treated with offlabel omalizumab in antihistamine-refractory cases, although real-world evidence on its long-term efficacy, drug survival and predictive biomarkers is limited. The aim was to evaluate the real-world efficacy and long-term drug survival of omalizumab in chronic inducible urticaria and to identify clinical and serological predictors of response and persistence. This retrospective, multicentre study included 144 patients with isolated chronic inducible urticaria treated with omalizumab. At 6 months, 73% of patients achieved complete or good disease control. Solar urticaria showed a higher rate of complete control (69%), with a significantly higher rate than symptomatic dermographism (32%; p=0.0246). Most patients were fast responders (83%) and 26% required updosing. Higher body mass index was associated with lower complete control [odds ratio (OR) 0.92; p=0.049] and a greater likelihood of dose escalation (OR 1.11; p=0.019). Overall drug survival was 95%, 87.5% and 72.4% at 1, 2 and 5 years, respectively. Discontinuation occurred in 33% of patients, primarily due to remission (50%). Exploratory analyses did not identify robust predictors of cause-specific discontinuation. In conclusion, omalizumab is effective and well tolerated in chronic inducible urticaria, providing sustained control and long-term drug survival; however, baseline clinical and serum biomarkers did not predict treatment response or drug survival.
Authors
- Alba Álvarez-Abella
- Maria Pilar Saura Foix (ORCID: https://orcid.org/0000-0001-7888-5302)
- Gemma Melé‐Ninot (ORCID: https://orcid.org/0000-0003-0365-0634)
- Jorge Spertino
- Antonio Guilabert Vidal
- Esther Serra‐Baldrich (ORCID: https://orcid.org/0000-0001-7603-0300)
- Jaume Martí‐Garrido (ORCID: https://orcid.org/0000-0003-0260-365X)
- Moisés Labrador‐Horrillo (ORCID: https://orcid.org/0000-0003-3222-2380)
- Montserrat Bonfill‐Ortí (ORCID: https://orcid.org/0000-0002-3183-7538)
- Vicente Expósito‐Serrano (ORCID: https://orcid.org/0000-0002-9256-1723)
- Paula Ribó (ORCID: https://orcid.org/0000-0002-9129-5347)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- David Pesqué (ORCID: https://orcid.org/0000-0002-5821-9780)
- Ignasi Figueras‐Nart (ORCID: https://orcid.org/0000-0001-9341-5923)
- Natalia Fernández-Chico
- Javier Fernández-Vela (ORCID: https://orcid.org/0000-0002-0113-6087)
- Anna Porta‐Vilaró (ORCID: https://orcid.org/0009-0002-8896-2329)
- Aguilera Paula
- Victoria Amat-Saramanch
Institutions
- Universitat Autònoma de Barcelona (ES)
- Universitat Pompeu Fabra (ES)
- Hospital de Sant Pau (ES)
- Bellvitge University Hospital (ES)
- Universitat Internacional de Catalunya (ES)
- University Hospital Mútua de Terrassa (ES)
- Consorci Sanitari de Terrassa (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital General de Granollers (ES)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Corporació Sanitària Parc Taulí (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Mútua Terrassa (ES)
- Hospital Universitari Sagrat Cor (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- Hospital del Mar Research Institute (ES)
Publication Details
- Journal
- Acta Dermato Venereologica
- Published
- 2026-11-18
- DOI
- https://doi.org/10.2340/actadv.v106.adv-2026-0875
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Celldex Therapeutics
- Allergy Therapeutics
- Celltrion
- Galderma
- Servier
- Mitsubishi Tanabe Pharma Corporation
- Genentech